for blt lovers , page-15

Alnylam Launches its RNAi 2010 Outlook for Key Scientific, Clinical, and Business...


2008 Goals and Guidance

Form Two or More Major New Alliances. In 2008, Alnylam intends
to form two or more new alliances with leading companies to
continue to develop and fund its growing pipeline of RNAi
therapeutics. This includes potential platform license
agreements such as the company's July 2007 collaboration with
Roche.


And guesse what Benitec already has in 2005 have in place
Agreement Includes Alnylam Grant to Benitec of Options to InterfeRx Licenses and Reciprocal Grants of Benitec IP to Alnylam

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Benitec Ltd. (Australian Stock Exchange: BLT), a leading developer of DNA-directed RNA interference therapeutics, announced today a licensing agreement covering fundamental intellectual property (IP) in the field of RNA interference (RNAi). Under the agreement, Alnylam will provide Benitec and its licensees an option to non-exclusively license Alnylam- controlled IP in the field of expressed RNAi: targeted gene silencing mediated by short interfering RNAs (siRNAs) generated from DNA constructs introduced into cells. Upon Benitec's exercise of this option, Alnylam would receive license fees and be entitled to receive milestone payments and royalties on any expressed RNAi products developed by Benitec or its licensees. Under the agreement, Benitec also provides Alnylam with reciprocal options under reciprocal terms to non-exclusively license Benitec IP for expressed RNAi and synthetic siRNAs.